Furthermore, utilizing Clue.io to identify candidate drugs to suppress AD-pathology reveals a plausible list of therapeutic candidates, including targeted genes and compounds such as <i>SMAD3, TM7SF2</i>, and <i>ABCB1</i>, which counteract the transcriptomic signature identified and may block the devastating effects of AD related to inflammatory responses, Aβ-induced toxicity, and neuronal death. Here, SMAD3 is linked to Alzheimer disease.